Literature DB >> 18083348

Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naïve schizophrenic patients.

G J E Schmitt1, C la Fougère, S Dresel, T Frodl, K Hahn, H-J Möller, E M Meisenzahl.   

Abstract

OBJECTIVE: The aim of this investigation was to evaluate the usefulness of a dual-isotope SPECT technique to assess simultaneously striatal dopamine binding structures - presynaptic dopamine transporter (DAT) and postsynaptic dopamine D(2) receptor - in first-episode, drug-naive schizophrenic patients compared to healthy control persons. Additionally, relations between radioligand binding to DAT and D(2) and positive symptoms were assessed.
METHODS: Twenty acutely ill inpatients suffering from a first acute schizophrenic episode and 12 healthy control persons participated in the study. Patients were naïve with respect to neuroleptic or antidepressant medication. A dual-isotope SPECT protocol was performed using combined application of [99mTc]TRODAT-1 and [123I]IBZM. On the day of SPECT, psychopathology was assessed in the patient group by PANSS rating.
RESULTS: In the patient but not in the healthy control group there was a significant correlation between DAT and D(2) receptor availability. Patients with predominant positive symptoms (n=12) had a significantly higher DAT availability compared to the healthy control group. An inverse correlation between DAT and D(2) availability and the extent of "delusions", "conceptual disorganization", and "hallucinatory behaviour" could be demonstrated. DISCUSSION: The data obtained with this dual-isotope SPECT technique show a change in interaction between striatal DAT and D(2) receptor in first-episode, never-treated schizophrenic patients. Additionally, an association between dopamine transmission and the core symptoms of the acute psychotic syndrome was found.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083348     DOI: 10.1016/j.schres.2007.11.010

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  13 in total

1.  An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?

Authors:  Ramadhan Oruch; Anders Lund; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2010-01-27

2.  Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

Review 3.  Presynaptic dopamine in schizophrenia.

Authors:  Nobumi Miyake; Judy Thompson; Mette Skinbjerg; Anissa Abi-Dargham
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

4.  Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients.

Authors:  G J E Schmitt; S Dresel; T Frodl; C la Fougère; R Boerner; K Hahn; H-J Möller; E M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-13       Impact factor: 5.270

5.  Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study.

Authors:  Eric Artiges; Claire Leroy; Manon Dubol; Marie Prat; Audrey Pepin; Audrey Mabondo; Renaud de Beaurepaire; Béatrice Beaufils; Jean-Pierre Korwin; André Galinowski; Marc-Antoine D'Albis; Maria-João Santiago-Ribeiro; Bernard Granger; Eleni T Tzavara; Jean-Luc Martinot; Christian Trichard
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

6.  How have developments in molecular imaging techniques furthered schizophrenia research?

Authors:  Judy L Thompson; Nina Urban; Anissa Abi-Dargham
Journal:  Imaging Med       Date:  2009-12-01

Review 7.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

8.  Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.

Authors:  James L Kennedy; Nian Xiong; Jinlong Yu; Clement C Zai; Jennie G Pouget; Jie Li; Kefu Liu; Hong Qing; Tao Wang; Eden Martin; Deborah L Levy; Zhicheng Lin
Journal:  Schizophr Bull       Date:  2015-12-26       Impact factor: 9.306

9.  Involvement of nigrostriatal pathway in Japanese encephalitis with movement disorders: evidence from 99mTc-TRODAT-1 and 123I-IBZM SPECT imagings.

Authors:  Chang-Hsu Liao; Zaodung Ling; Chung-Hsing Chou; Wen-Sheng Huang; Jong-Chyou Denq; Jiann-Chyun Lin; Cheng-Yu Chen; Chia-Jung Chang; Giia-Sheun Peng
Journal:  Mol Imaging Biol       Date:  2009-06-23       Impact factor: 3.488

10.  Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis.

Authors:  Kao Chin Chen; Yen Kuang Yang; Oliver Howes; I Hui Lee; Sabine Landau; Tzung Lieh Yeh; Nan Tsing Chiu; Po See Chen; Ru Band Lu; Anthony S David; Elvira Bramon
Journal:  Schizophr Bull       Date:  2011-12-08       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.